Healthcare
Diagnostics & Research
$169.37B
63K
Key insights and themes extracted from this filing
Consolidated revenues were flat year-over-year, with core sales declining driven by the Biotechnology and Life Sciences segments, partially offset by growth in Diagnostics. This indicates potential challenges in specific markets or product lines.
Net earnings attributable to common stockholders decreased from $4.7 billion in 2023 to $3.9 billion in 2024, driven by intangible asset impairments and increased operating expenses. This suggests cost management efforts were insufficient to offset negative factors.
Operating cash flow increased 3% YoY, primarily due to improvements in trade accounts receivable, inventories, and trade accounts payable. This indicates improved efficiency in working capital management.